周二发表在医学期刊《柳叶刀》(Lancet)上的一项研究显示，在中国的一个小规模试验中，自今年年初以来已造成36人死亡的H7N9禽流感病毒对流感疫苗达菲(Tamiflu)显示出抗药性。这项研究指出，14名在上海市公共卫生临床中心接受抗病毒药物治疗的患者中，有三名在接受治疗期间病情变得非常严重。这暗示抗病毒治疗没有减少患者的病毒载量。病毒载量是衡量感染严重程度的一项指标。这三名患者中有两名死亡，而另一名患者需要复杂的治疗，以便为血液补充氧气。
The bird-flu strain H7N9 virus that has killed 36 people since the beginning of the year has shown resistance to flu vaccine Tamiflu in a small-scale trial in China, according to research published Tuesday in the Lancet medical journal.
这14名患者均有肺炎，但在接受一类被称为神经氨酸 抑制剂的抗病毒药物治疗期间，大多数患者的病毒载量下降。上述抗病毒药物包括罗氏公司(Roche Holding AG.)生产的达菲。
Three out of 14 patients treated with antiviral drugs at the Shanghai Public Health Clinical Center became severely ill while undergoing treatment, according to the research, which suggested antiviral treatment didn't reduce their viral load, a measure of the severity of the infection. Two of the three patients died, while the third required a complicatedtreatment to reoxygenate his blood.
《柳叶刀》杂志周二在一份新闻稿中说，研究人员怀疑在这些病例中，H7N9病毒已经对抗病毒药物产生抗药性。
All of the 14 patients had pneumonia, but most showed a reduction in the viral load during treatment with a class of antiviral drugs called neuraminidase inhibitors, which includes Tamiflu, manufactured by Roche Holding ROG.VX -0.12% AG.
研究人员说，在一名患者身上发现有证据表明，抗药性可能是使用达菲治疗造成的结果。这导致研究人员担心，神经氨酸 抑制剂疗法可能会引发抗药性。神经氨酸 抑制剂是针对流感病毒的一类抗病毒药物。
The researchers suspect the H7N9 virus has become resistant to the antiviral drugs in these cases, the Lancet said in a press release Tuesday.
这项研究的作者在声明中说，H7N9病毒对抗病毒药物轻易展现出的抗药性令人担忧。这一问题需要密切监测，在未来制定流行病应急方案时需要加以考虑。但研究人员也指出，使用这些药物进行早期治疗仍然是应对这一病毒的最佳手段。
In one patient, researchers said, there was evidence the resistance probably developed as a result of treatment with Tamiflu, leading to concerns that resistance might arise in response to treatment with neuraminidase inhibitors
京公网安备 11011202003401号
